Role of enteral nutrition in nonthyroidal illness syndrome: a retrospective observational study by Ranran Li et al.
RESEARCH ARTICLE Open Access
Role of enteral nutrition in nonthyroidal
illness syndrome: a retrospective
observational study
Ranran Li, Jianan Ren*, Qin Wu, Gefei Wang, Xiuwen Wu, Jun Chen, Guanwei Li, Zhiwu Hong, Huajian Ren,
Yunzhao Zhao and Jieshou Li
Abstract
Background: The nonthyroidal illness syndrome (NTIS) is prevalent among patients with enterocutaneous fistula
and is associated with poor outcomes. The present study aimed to explore the role of enteral nutrition (EN) therapy
on thyroid function among patients with enterocutaneous fistula and NTIS.
Methods: We conducted a retrospective observational study among patients with enterocutaneous fistula between
January 2013 and April 2014. All enrolled patients received EN therapy. Thyroid function and other parameters were
measured.
Results: After administration of 4 weeks of EN therapy, NTIS was resolved in 66 patients (Group A), while it persisted in
14 patients (Group B). The overall treatment success rate was 82.50 %. There were no significant differences between
groups A and B at baseline for all parameters, except for the time from admission to start of EN therapy. The logistic
analysis revealed that the time from admission to start of EN therapy was a significant independent indicator for
achieving resolution of NTIS in our cohort.
Conclusions: This retrospective observational cohort study demonstrated that EN therapy can aid in the resolution of
NTIS among patients with enterocutaneous fistula. These findings confirm the benefit of EN in the treatment of
enterocutaneous fistula.
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Background
Changes in the endocrine system that result from critical
illnesses can cause multiple dysfunctions [1]. Also known
as the euthyroid sick syndrome, the nonthyroidal illness
syndrome (NTIS) commonly affects patients with entero-
cutaneous fistula [1, 2]. This syndrome is characterized by
alterations in thyroid function, which are commonly
reflected as low serum triiodothyronine (T3) and normal
to low thyroxine (T4). Studies have suggested that low
levels of thyroid hormones are predictors of poor outcome
in sepsis and critical illness [3]. In our previous study, we
reported an association between NTIS and poor outcome
among patients with enterocutaneous fistula, indicating
the clinical importance of these alterations [1].
To date, the pathogenesis of these endocrine alterations
in NTIS is not fully understood. Previous studies have
reported several approaches for improving thyroid func-
tion in different patient populations with NTIS [4–6].
Some studies suggested the association between nutri-
tional deficiency and NTIS, indicating a potential role of
enteral nutrition (EN) therapy in resolving NTIS [7, 8].
Conversely, other studies reported that underlying illness
plays a key role in NTIS, suggesting that EN therapy
would not be expected to aid in the resolution of the thy-
roid abnormalities [9, 10]. Because the prevalence of NTIS
among patients with enterocutaneous fistula is increasing,
we conducted a retrospective observational study to inves-
tigate the role of EN therapy in the resolution of NTIS.
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This retrospective, observational cohort study was con-
ducted in accordance with the principles of good clinical
practice and the Declaration of Helsinki. The study
protocol was reviewed and approved by the Institutional
Review Board at Jingling Hospital. Informed consent was
not obtained as patient records and information were
anonymized and de-identified prior to the study.
Patients and study design
Based on a detailed medical chart review, we primarily
enrolled consecutive patients with enterocutaneous fis-
tula admitted between January 2013 and April 2014. The
standard values of the variables assessed at our hospital
are as follows: free triiodothyronine (FT3), 3.8–6.5 pmol/L;
total triiodothyronine (TT3), 1.23–3.07 nmol/L; free thy-
roxin (FT4), 7.9–17.2 pmol/L; total thyroxin (TT4),
71–161 nmol/L; and thyroid stimulating hormone
(TSH), 0.3–4.5 mU/L.
The criteria for NTIS applied in our study were as fol-
lows: (1) FT3 level less than 3.8 pmol/L and (2) TSH
upper normal limit of 4.5 mU/L [2, 10]. In our depart-
ment, all patients underwent thyroid homeostasis mea-
surements upon admission for NTIS scanning, and a
thyroid test every week to evaluate the thyroid function.
Records of patients with NTIS at admission were pri-
marily collected. The exclusion criteria were as follows
(1) current use of EN, thyroid hormone and antithyroid
drugs at admission; (2) history of coronary artery dis-
ease, myocardial infarction or cerebral infarction in the
past month upon admission; (3) pregnancy or lactation;
(4) a previous history of thyroidal, hypophyseal or hypo-
thalamic disease; (5) age less than 18; (6) craniocerebral
injury; (7) end-stage advanced malignant tumor; (8)
medication history of thyroid hormone or antithyroid
drugs; (9) and intracranial infection or hemorrhage in
the past month. After excluding patients, clinical data of
the remaining patients were collected to constitute our
cohort. The observational period was limited to 4 weeks.
The time point at admission was defined as week 0.
The primary outcome of our study was defined as the
resolution of NTIS at week 4 after admission. We de-
fined in this study that patients whose FT3 level is above
3.8 pmol/L at week 4 are those who recovered from
NTIS. At the end of the study, patients who experienced
resolution of NTIS in this cohort were assigned to
Group A while others were assigned to Group B.
EN therapy
In our department, the EN used for patients with enterocu-
taneous fistula was Peptisorb Liquid (Enteral Nutrition
Fig. 1 Flowchart of the current study. In total, 90 consecutive patients with NTIS were retrospectively enrolled from 140 patients with enterocutaneous
fistula. Ten patients were excluded based on the exclusion criteria checking, and 80 patients were finally included
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Suspension; Nutricia Company, Amsterdam, Holland).
Once the output of intestinal fluid was limited (<200 ml/L)
and patients were satisfactorily maintained on enteral
feeding, EN was gradually introduced to reach full feed-
ing. The EN therapy in our study was conducted as
described in our previous study [11]. Briefly, EN was
prescribed through a nasogastric or nasointestinal tube.
The formula contained 1 cal/mL and had 500 kcal/
bottle. The energy requirements were calculated using
Long’s modified equation according to the usual body
weight. No oral foods or fluids (except for water and
weak tea) were allowed. The nutrition regimen during
the study period remained almost unchanged.
Data collection
For each enrolled patient, the following data were collected
from the medical record: primary diseases, fistula location,
underlying disease, Acute Physiology and Chronic Health
Evaluation Score (APACHE II), time for initiation of en-
teral nutrition upon admission, white blood cell count
(WBC), C-reactive protein (CRP), red blood cell count
(RBC), platelet count (PCs), glutamic-pyruvic transaminase
(GPT) and blood urine creatinine (Cr), FT3, TT3, FT4,
TT4 and TSH. Baseline characteristics, including age and
sex, were also collected.
In our department, venous blood for all laboratory
tests was drawn between 5 am and 6 am. Serum indexes,
including WBC, CRP, RBC, PCs, Cr, GPT FT3, TT3,
FT4, TT4 and TSH were measured at least once a week
to monitor the patients’ status. Laboratory values were
calculated within 2 h after blood collection.
Statistical analysis
Demographic data and laboratory parameters were sum-
marized by frequency for categorical variables and
means ± standard deviation (SD). The proportions were
compared with chi-square test or Fisher’s exact test.
Continuous variables were tested by means of the t-test
with normal distribution or Wilcoxon rank-sum test
with non-normal distribution. A logistic analysis was
performed to assess the influence of each variable on
treatment success rate. Survival analysis was conducted,
and statistical analyses were performed with GraphPad
Prism Software (version 5.01; GraphPad, San Diego, CA,
USA) and SAS software (SAS 9.1.3; SAS Institute Inc.,




In total, 140 consecutive patients with enterocutaneous
fistula were admitted to our department from January
2013 and April 2014. We retrospectively enrolled 90
consecutive patients with enterocutaneous fistula who
met the NTIS criteria as primary inclusion. Ten patients
met the exclusion criteria and were excluded from the
study. Therefore, the final study cohort consisted of 80
patients (Fig. 1).
The general clinical characteristics of the study group
at admission are presented in Table 1. Among the 80
cases, there were 58 males and 22 females (male-to-
female ratio, 2.64:1). Patient had a mean (±SD) age of
48.05 ± 13.43 years. The most common causes for
enterocutaneous fistula development in our study were
trauma and surgical complications. The most common
location of enterocutaneous fistula was the small bowel.
A total of 24 patients had a positive history of diabetes
mellitus, and 12 had chronic obstructive pulmonary
diseases. The time from admission to start of EN ther-
apy varied during our observational period. During the
EN treatment, 8 patients (9.76 %) had diarrhea caused
by the EN infusion, and symptoms were managed as
stated in the medical records. None of the patients
Table 1 General clinical condition of the study group at
admission
Parameters All subjects (N = 80)
Gender (Male, n %) 58 (72.50 %)
Age (yrs, mean ± SD) 48.05 ± 13.43
Severity scores, mean ± SD
APACHE II score 16.27 ± 2.05
Primary diagnosis (n %)
Trauma/Surgery complication 50 (62.50 %)
IBD 16 (20.00 %)
Pancreatitis 6 (7.50 %)
Others 8 (10.00 %)
Fistula location
Duodenum 12 (15.00 %)
Colon 16 (20.00 %)
Small bowel 32 (40.00 %)
Multiple visceraa 20 (25.00 %)
Underlying disease, n ( %)
Untreated cancer 8 (10.00 %)
DM 24 (30.00 %)
COPD 12 (15.00 %)
None 36 (45.00 %)
Time for initiation of enteral nutrition, n ( %)
< 7 day 20 (25.00 %)
7–14 days 30 (37.50 %)
15–21 days 22 (27.50 %)
> 22 days 8 (10.00 %)
IBD inflammatory bowel diseases, DM diabetes mellitus, COPD chronic
obstructive pulmonary diseases, LOS length of stay, IQR interquartile range
aMultiple viscera includes small bowel/colon, duodenum/small bowel or
pancreas/duodenum/small bowel
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discontinued EN because of poor tolerance to EN ther-
apy during the study period. No mortality occurred
among the cohorts.
Changes in thyroid function
Figure 2 and Additional file 1: Tables S1 shows the
changes of thyroid function in this cohort during the
observational period. During our observational period,
serum FT3 concentrations were significantly increased,
from 3.02 ± 0.138 at the baseline to 4.13 ± 0.052 in the
last week (p <0.001), while serum level of FT4, TT4 and
TSH kept stable during our observation.
According to our definition, 66 patients experienced
resolution of NTIS (Group A) while 14 patients did not
(Group B). The overall treatment success rate for both
groups was 82.50 % (66/80). Table 2 presents the gen-
eral clinical condition of both groups. The time from
admission to start for EN therapy was significantly differ-
ent between Groups A and B. Thyroidal function changes
between those two groups in our study were displayed in
Fig. 2 and Additional file 2: Table S2. Serum FT3 and TT3
level increased significantly faster in group A compared
with those in group B. At the end of the second week after
admission, serum FT3 and TT3 in group A were signifi-
cantly higher than those in group B.
The logistic regression were performed with vari-
ables that associated with treatment success, respect-
ively, in our study, including age, gender, primary
diagnosis, fistula location, underlying disease, APA-
CHEIIscore and time for initiation of enteral nutrition,
to demonstrate their association with treatment suc-
cess. Table 3 revealed that initial time of EN was a sig-
nificant independent indicator with treatment success
in our cohort.
Fig. 2 Changes of thyroidal function during the observational period. Serum (a) FT3 and (c) TT3 kept significantly increasing in group A compared
with group B while other index [(b) FT4, (d) TT4 and (e) TSH] remained stable. (* indicated a significant difference between group A and group B)
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Status of other serum indices
Table 4 shows the changes of other serum indices mea-
sured in our study. For all patient populations, all the
laboratory tests presented no significant differences over
time, except for some isolated indices. CRP kept de-
creasing over time in our study and reached a signifi-
cantly low level at the end of our observational period.
The same trend was observed for GPT. PCs in all popu-
lations kept increasing to a relatively normal level. In
subgroup analysis, changes of serum indices measured
in our study shared a similar trend between groups,
without any significant differences between Groups A
and B.
Discussion
In the current study, we retrospectively enrolled patients
with NTIS admitted at our center and investigated the
role of EN therapy in the treatment of NTIS. We ob-
served that 66 out of 80 patients experienced resolution
of NTIS after EN therapy. Further, we compared the
clinical information between groups in terms of efficacy.
A comparison between Groups A and B indicated that
Table 2 General clinical condition of the group A and group B at admission
Parameters Group A (N = 66) Group B (N = 14) P
Gender (Male, n %) 48 (72.72 %) 10 (71.43 %) 0.944
Age (yrs, mean ± SD) 47.69 ± 13.03 48.71 ± 15.17 0.708
Severity scores, mean ± SD
APACHE II score 15.64 ± 1.29 16.47 ± 2.87 0.248
Primary diagnosis (n %) 0.679
Trauma/Surgery complication 44 (66.67 %) 6 (42.86 %)
IBD 12 (18.18 %) 4 (28.57 %)
Pancreatitis 4 (6.06 %) 2 (14.29 %)
Others 6 (9.09 %) 2 (14.29 %)
Fistula Location 0.139
Duodenum 10 (15.15 %) 2 (14.29 %)
Colon 16 (24.24 %) 0 (0.00 %)
Small bowel 28 (42.42 %) 4 (28.57 %)
Multiple visceraa 12 (18.18 %) 8 (57.14 %)
Underlying disease, n (%) 0.634
Untreated cancer 6 (9.09 %) 2 (14.29 %)
DM 20 (30.30 %) 4 (28.57 %)
COPD 12 (18.18 %) 0 (0.00 %)
None 28 (42.42 %) 8 (57.14 %)
Time for initiation of enteral nutrition, n (%) 0.013
< 7 day 18 (27.27 %) 2 (14.29 %)
7–14 days 28 (42.42 %) 2 (14.29 %)
15–21 days 18 (27.27 %) 4 (28.57 %)
>22 days 2 (3.03 %) 6 (42.86 %)
Hospital cost, median (IQR), dollar 28,502.82 (31,494) 32,042.04 (28,492) 0.003
WBC, ×109/L, mean ± SD 10.30 ± 6.31 10.54 ± 1.47 0.123
CRP, mg/L, mean ± SD 73.53 ± 62.11 71.82 ± 25.11 0.223
RBC, ×109/L, mean ± SD 3.21 ± 0.73 3.16 ± 0.54 0.705
GPT, U/L, mean ± SD 46.62 ± 25.36 44.27 ± 17.96 0.512
PCs, ×109/L, mean ± SD 126.48 ± 82.38 122.66 ± 78.53 0.189
Cr, umol/L, mean ± SD 56.28 ± 49.98 53.50 ± 34.59 0.661
P value was calculated between group A and group B
IBD inflammatory bowel diseases, DM diabetes mellitus, COPD chronic obstructive pulmonary diseases, LOS length of stay, IQR interquartile range, WBC white
blood cell counts, CRP C-reactive protein, RBC red blood cell counts, PCs platelet counts, GPT glutamic-pyruvic transaminase, Cr blood urine creatinine
aMultiple viscera includes small bowel/colon, duodenum/small bowel or pancreas/duodenum/small bowel
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the time from admission to start of EN therapy was sig-
nificantly different. Results from logistic regression ana-
lysis revealed that the time from admission to start of
EN was a significant independent indicator of NTIS out-
come. To our knowledge, this is the first study to focus
on the potential role of EN in patients with NTIS and
enterocutaneous fistula.
The term NTIS is used to describe the deranged TH
profile observed in nonthyroidal illnesses that is charac-
terized mainly by decreased serum T3 and⁄or T4 and in
some cases suppressed TSH levels [12]. NTIS is a com-
mon alteration in thyroid function observed in about
70 % of hospitalized patients, with or without acute
systemic illnesses [13]. In this study, the prevalence of
NTIS among patients with enterocutaneous fistula was
64.28 % (90/140), which accorded with our previous
study, showing the prevalence of this alteration [1].
It was proven that thyroid function abnormalities can
occur within hours of acute illness, and the magnitude
of these alterations correlates with the severity of the
disease. Additionally, the lowest T3 and T4 values are as-
sociated with decreased survival [2]. Several studies have
reported the association between NTIS and poor outcome
[14, 15]. Our previous study also showed that patients
with enterocutaneous fistula and NTIS presented worse
clinical outcome and prognosis [1].
The etiology of the NTIS has been demonstrated to be
multifactorial. It has been suggested that increased levels of
endogenous or exogenous glucocorticoids, cytokines and
catecholamines are implicated in the dysregulation of thy-
roid hormones [16–18]. The increased levels of these
substances, occurring in conjunction with critical illness
and severely hypocaloric diets, favor the conversion of T4
[19, 20]. Changes in thyroid function are commonly seen
as adaptive changes in times of stress. However, consider-
ation has also been given to the possibility that patients
who have NTIS may not respond to elevated TSH because
of central hypothyroidism secondary to systemic illness [2].
Several studies have examined the efficacy of treating
NTIS with thyroxine administration, but the results were
inconclusive and controversial [21]. The recovery of thy-
roid function after administration of EN in patients with
NTIS indicates the potential role of EN in reversing
NTIS [22]. In this study, we observed an improvement
in thyroid function in a cohort of patients with entero-
cutaneous fistula after EN therapy. A total of 82.50 %
(66/80) patients experienced resolution of NTIS, indicat-
ing a beneficial role of EN in NTIS.
We further compared the general clinical condition
between Groups A and B to investigate the differences
between patients who recovered from NTIS after EN ther-
apy and those who did not. Based on that comparison, we
found that the difference between groups was the time
from admission to start of EN therapy. In the logistic
analysis, we chose 2 week as the threshold because the
median initial time of EN therapy in our patient cohorts is
closed to that. We found that patients who received EN
therapy within 2 weeks after 2 weeks have a significantly
higher chance to recovery from NTIS.
The improvement in thyroid function that we ob-
served after EN therapy in this study may be ascribed to
multiple factors. EN therapy may have a direct impact
on thyroid function or it may exert an indirect effect by
influencing the prognosis of the primary disease. Be-
cause the changes of the underlying disease during the
treatment were not significantly different between both
groups (shown in Table 4), we speculate that EN exerts
a direct effect on the improvement of the thyroid func-
tion that led to the resolution of NTIS, rather than on
underlying diseases among enterocutaneous fistula pa-
tients. From this study, we can also conclude that add-
itional thyroxine is not needed in patients under EN
therapy with NTIS. Still, a well-designed randomized
clinical study is needed to draw a definitive conclusion.
Table 3 Multivariate analysis of time for initiation of enteral
nutrition and other covariates associated with NTIS recovery
Variables Hazard
ratio
95 % CI P
valuelower upper
Age
> 48 20.829 0.639 679.079 0.088
= <48 1.000 – – –
Gender
Male 1.000 – – –
Female 0.019 0.001 764.165 0.115
Primary diagnosis
Non- surgical complication 10.030 0.149 674.056 0.283
Surgical complication 1.000 – – –
Fistula Location
Single 1.000 – – –
Multiple 0.037 0.001 1.093 0.058
Underlying disease
Yes 1.000
No 1.405 0.104 18.898 0.798
APACHE II
> 16 1.000
= <16 1.461 0.869 2.456 0.152
FT3 at the baseline
> 3.02 1.000 – – –
= <3.02 0.213 0.009 5.272 0.345
Time for initiation of enteral nutrition
= <2 week 28.204 1.041 764.165 0.047
> 2 week 1.000 – – –
FT free thyroxin, 95 % CI 95 % confidence interval
Li et al. BMC Endocrine Disorders  (2015) 15:69 Page 6 of 8
The observational period in our study was limited to
4 weeks because the average hospital stay for patients with
enterocutaneous fistula who were admitted to our depart-
ment was around 4 weeks. Usually, patients with enterocu-
taneous fistula would be admitted to our department to
control infection and maintain homeostasis. When the clin-
ical condition of patients was stable, they would be trans-
ferred to another ward. Once a stable condition and
homeostasis were achieved, they would return to our de-
partment for definitive surgery. Measurement of thyroid
function parameters was not available for our cohort after
hospital discharge. Thus, this study was limited to 4 weeks
of hospitalization.
The present study has several limitations. First, this
was just a retrospective observational cohort study from
a single medical center. Seasonably, data from different
regional hospitals might increase the external validity of
our conclusions. Second, as a retrospective study, the
validity of our conclusions might increase if the sample
size was expanded. In our study, we did not include indi-
ces that affected the nutritional status because of the
short observational period. We excluded patients with
varied comorbidities which limited our patient cohorts.
Finally, well-organized randomized, double-blind clinical
trials and systematic analysis of the role of EN in entero-
cutaneous fistula patients with NTIS are needed.
Table 4 Laboratory tests of all enrolled patients after admission
Time Parameters All subjects (N = 80) Group A (N = 66) Group B (N = 14) P-valuea P-valueb
Baseline WBC, ×109/L, mean ± SD 10.35 ± 6.52 10.30 ± 6.31 10.54 ± 1.47 0.785 –
CRP, mg/L, mean ± SD 72.03 ± 54.21 73.53 ± 62.11 71.82 ± 25.11 0.496 –
RBC, ×109/L, mean ± SD 3.17 ± 0.68 3.21 ± 0.73 3.16 ± 0.54 0.389 –
GPT, U/L, mean ± SD 45.21 ± 28.03 46.62 ± 25.36 44.27 ± 17.96 0.443 –
PCs, ×109/L, mean ± SD 124.67 ± 62.42 126.48 ± 82.38 122.66 ± 78.53 0.453 –
Cr, umol/L, mean ± SD 54.78 ± 54.11 56.28 ± 49.98 53.50 ± 34.59 0.557 –
Week 1 WBC, ×109/L, mean ± SD 9.87 ± 5.17 9.89 ± 5.34 9.35 ± 3.47 0.745 0.466
CRP, mg/L, mean ± SD 42.58 ± 27.47 43.61 ± 28.18 40.91 ± 11.85 0.058 0.022
RBC, ×109/L, mean ± SD 3.19 ± 0.72 3.20 ± 0.78 3.18 ± 0.17 0.177 0.597
GPT, U/L, mean ± SD 36.01 ± 22.28 37.82 ± 13.51 35.29 ± 10.83 0.581 0.180
PCs, ×109/L, mean ± SD 141.81 ± 57.02 143.69 ± 52.76 140.11 ± 12.54 0.184 0.388
Cr, umol/L, mean ± SD 52.47 ± 43.73 54.20 ± 19.97 51.86 ± 7.09 0.588 0.806
Week 2 WBC, ×109/L, mean ± SD 10.01 ± 6.13 10.12 ± 7.22 9.89 ± 2.25 0.685 0.631
CRP, mg/L, mean ± SD 28.62 ± 37.38 30.88 ± 23.48 26.69 ± 20.87 0.047 0.017
RBC, ×109/L, mean ± SD 3.21 ± 0.71 3.22 ± 0.23 3.19 ± 0.50 0.472 0. 614
GPT, U/L, mean ± SD 29.12 ± 12.38 30.24 ± 16.57 28.59 ± 14.87 0.841 0.158
PCs, ×109/L, mean ± SD 153.32 ± 37.32 155.54 ± 56.77 151.08 ± 39.52 0.687 0.069
Cr, umol/L, mean ± SD 43.55 ± 27.31 45.13 ± 16.47 42.32 ± 37.54 0.343 0.635
Week 3 WBC, ×109/L, mean ± SD 9.92 ± 4.38 9.96 ± 3.82 9.84 ± 2.87 0.776 0.508
CRP, mg/L, mean ± SD 18.52 ± 10.41 19.13 ± 13.13 18.23 ± 9.33 0.214 0.012
RBC, ×109/L, mean ± SD 3.20 ± 0.85 3.22 ± 0.93 3.19 ± 0.12 0.462 0.607
GPT, U/L, mean ± SD 21.61 ± 9.12 22.47 ± 12.92 20.38 ± 7.23 0.596 0.031
PCs, ×109/L, mean ± SD 176.66 ± 50.56 178.89 ± 67.53 175.12 ± 24.68 0.295 0.045
Cr, umol/L, mean ± SD 37.93 ± 15.09 39.55 ± 10.89 35.23 ± 27.42 0.493 0.431
Week 4 WBC, ×109/L, mean ± SD 9.16 ± 5.23 9.20 ± 7.89 9.12 ± 3.69 0.823 0.383
CRP, mg/L, mean ± SD 14.11 ± 6.17 14.55 ± 7.95 19.39 ± 3.98 0.069 0.005
RBC, ×109/L, mean ± SD 3.22 ± 0.44 3.25 ± 0.59 3.20 ± 0.34 0.406 0.621
GPT, U/L, mean ± SD 18.73 ± 9.91 19.72 ± 8.26 17.87 ± 7.40 0.622 0.010
PCs, ×109/L, mean ± SD 187.53 ± 15.93 189.37 ± 26.71 185.72 ± 42.46 0.641 0.033
Cr, umol/L, mean ± SD 35.64 ± 28.54 37.87 ± 27.95 33.34 ± 18.92 0.838 0.385
WBC white blood cell counts, CRP C-reactive protein, RBC red blood cell counts, PCs platelet counts, GPT glutamic-pyruvic transaminase, Cr blood urine creatinine
aP value is compared between group A and group B
bP value is compared between the index at varied time point and the same index at the baseline among all subjects
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Conclusions
In conclusion, this retrospective observational cohort
study demonstrated that EN therapy can aid resolution
of NTIS in enterocutaneous fistula patients. These find-
ings confirm the benefit of EN in the treatment of enter-
ocutaneous fistula. Further studies are expected to
investigate the underlying mechanisms of this effect in
the future.
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